MX2023003424A - Composiciones y metodos para inhibir la expresion genica. - Google Patents

Composiciones y metodos para inhibir la expresion genica.

Info

Publication number
MX2023003424A
MX2023003424A MX2023003424A MX2023003424A MX2023003424A MX 2023003424 A MX2023003424 A MX 2023003424A MX 2023003424 A MX2023003424 A MX 2023003424A MX 2023003424 A MX2023003424 A MX 2023003424A MX 2023003424 A MX2023003424 A MX 2023003424A
Authority
MX
Mexico
Prior art keywords
compositions
methods
gene expression
inhibiting gene
expression
Prior art date
Application number
MX2023003424A
Other languages
English (en)
Spanish (es)
Inventor
Jodi Michelle Kennedy
Jeremiah Dale Farelli
Original Assignee
Flagship Pioneering Innovations V Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations V Inc filed Critical Flagship Pioneering Innovations V Inc
Publication of MX2023003424A publication Critical patent/MX2023003424A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01043—Histone-lysine N-methyltransferase (2.1.1.43)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2023003424A 2020-09-24 2021-09-24 Composiciones y metodos para inhibir la expresion genica. MX2023003424A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063082555P 2020-09-24 2020-09-24
US202163242957P 2021-09-10 2021-09-10
PCT/US2021/051945 WO2022067033A1 (en) 2020-09-24 2021-09-24 Compositions and methods for inhibiting gene expression

Publications (1)

Publication Number Publication Date
MX2023003424A true MX2023003424A (es) 2023-05-03

Family

ID=80845810

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003424A MX2023003424A (es) 2020-09-24 2021-09-24 Composiciones y metodos para inhibir la expresion genica.

Country Status (7)

Country Link
US (1) US20230399640A1 (cg-RX-API-DMAC7.html)
EP (1) EP4217477A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023543218A (cg-RX-API-DMAC7.html)
KR (1) KR20230074525A (cg-RX-API-DMAC7.html)
AU (1) AU2021350024A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023003424A (cg-RX-API-DMAC7.html)
WO (1) WO2022067033A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
WO2018049075A1 (en) 2016-09-07 2018-03-15 Flagship Pioneering, Inc. Methods and compositions for modulating gene expression
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
EP4240367A4 (en) 2020-11-04 2024-10-16 Myeloid Therapeutics, Inc. MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
KR20240013094A (ko) 2021-03-17 2024-01-30 마이얼로이드 테라퓨틱스, 인크. 조작된 키메라 융합 단백질 조성물 및 그의 사용 방법
WO2022241029A1 (en) 2021-05-11 2022-11-17 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
US20250236854A1 (en) * 2021-10-05 2025-07-24 Glaxosmithkline Intellectual Property Development Limited GSK Medicines Research Centre Crispr/cas9-based fusion proteins for modulating gene expression and methods of use
WO2024040254A2 (en) * 2022-08-19 2024-02-22 Tune Therapeutics, Inc. Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
KR20250128349A (ko) * 2022-12-23 2025-08-27 에피제닉 테라퓨틱스 피티이 리미티드 융합체 및 이의 용도
JP2026518711A (ja) 2023-05-16 2026-06-09 フラッグシップ ラブズ 114, インコーポレイテッド 標的遺伝子のメチル化を調節するための方法及び組成物
WO2024238723A1 (en) 2023-05-16 2024-11-21 Omega Therapeutics, Inc. Methods and compositions for modulating pcsk9 expression
WO2025019742A1 (en) 2023-07-19 2025-01-23 Omega Therapeutics, Inc. Methods and compositions for modulating ctnnb1 expression
WO2025064469A1 (en) * 2023-09-18 2025-03-27 Omega Therapeutics, Inc. Methods for assessing dosage for epigenetic modifying agents
WO2025171047A1 (en) * 2024-02-05 2025-08-14 Bioventures, Llc Leveraging cancer-evolved resistance mechanisms to enhance ezh2 activity in adoptive t cells
WO2025261475A1 (zh) * 2024-06-21 2025-12-26 益杰立科(上海)生物科技有限公司 靶向血管内皮生长因子的工程化基因转录阻抑工具及用途
WO2026064556A1 (en) * 2024-09-19 2026-03-26 Arc Research Institute Epigenetic modulation system

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2728782T3 (es) * 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
GB201418965D0 (cg-RX-API-DMAC7.html) * 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
AU2016308339A1 (en) * 2015-08-18 2018-04-12 Baylor College Of Medicine Methods and compositions for altering function and structure of chromatin loops and/or domains
US9896696B2 (en) * 2016-02-15 2018-02-20 Benson Hill Biosystems, Inc. Compositions and methods for modifying genomes
EP3867368A4 (en) * 2018-10-15 2022-08-10 Flagship Pioneering Innovations V, Inc. DESTROYING THE ASSEMBLY OF A GENOMIC COMPLEX IN FUSION GENES
WO2020160125A1 (en) * 2019-01-29 2020-08-06 Flagship Pioneering Innovations V, Inc. Compositions comprising an endonuclease and methods for purifying an endonuclease

Also Published As

Publication number Publication date
WO2022067033A1 (en) 2022-03-31
EP4217477A1 (en) 2023-08-02
EP4217477A4 (en) 2024-10-16
AU2021350024A9 (en) 2023-07-13
AU2021350024A1 (en) 2023-05-04
KR20230074525A (ko) 2023-05-30
JP2023543218A (ja) 2023-10-13
US20230399640A1 (en) 2023-12-14

Similar Documents

Publication Publication Date Title
MX2022010991A (es) Metodos y composiciones para modular un genoma.
MX2025014205A (es) Composiciones y metodos para expresar el factor ix
PH12021552613A1 (en) METHODS AND COMPOSITIONS FOR EDITING RNAs
EP4306116A3 (en) Methods and compositions for editing rnas
MX2019011469A (es) Inhibidores del mir-155 para tratar linfoma cutaneo de celulas t (ctcl).
AU2017261380A1 (en) Genetically engineered cells and methods of making the same
MX2024007924A (es) Edicion genomica multiplexada.
WO2018217064A3 (ko) 형질전환된 t세포를 이용한 자연살해세포의 배양방법
UY35088A (es) Inhibidores de glutamina sintetasa de planta y métodos para su identificación
WO2018097540A3 (ko) 무혈청면역세포배양용 배지첨가키트, 상기 키트를 이용한 면역세포배양방법, 상기 키트 또는 배양방법에 의해 얻어진 무혈청면역세포배양액 및 상기 배양액을 포함하는 화장료조성물
PH12021551475A1 (en) Heterodimeric proteins for modulating gamma delta t cells
EP4438734A3 (en) Reprogramming of cells to a new fate
MX2018005692A (es) Limitación de trehalosa producida por levaduras en fermentación.
MX2015012452A (es) Inhibición o reducción del crecimiento de hongos.
MX2023007116A (es) Composiciones y metodos para modular la expresion de myc.
MX2019005476A (es) Ensayo de celulas madre pluripotentes.
MX2018009247A (es) Uso de inhibidores de histona deacetilasa para aumentar las inmunoterapias.
WO2020205626A8 (en) Modulators of cell surface protein interactions and methods and compositions related to same
MY203884A (en) Taurine supplemented cell culture medium and methods of use
PH12018502061A1 (en) Differentiation of pluripotent stem cells to intestinal midgut endoderm cells
MX2024002930A (es) Metodos y composiciones para modular un genoma.
WO2021231263A3 (en) Nucleic acid amplification methods
ZA202306751B (en) Plant-based synthesis products
PH12020552291A1 (en) System and methods for engineering bacteria fit for eukaryotic mrna production, export, and translation in a eukaryotic host
MX2022012829A (es) Metodo para tratamiento de medio antes de inoculacion.